Is tirzepatide (a dual GIP and GLP-1 receptor agonist) safe to use in a breastfeeding woman with type 2 diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tirzepatide and Breastfeeding

Tirzepatide should not be used during breastfeeding due to lack of safety data and the availability of well-established safe alternatives such as insulin, metformin, glyburide, or glipizide.

Evidence Against Tirzepatide Use During Lactation

The American College of Cardiology guidelines specifically list "the patient is breastfeeding" as a consideration that prompts caution or avoidance of GLP-1 receptor agonists like tirzepatide 1. While tirzepatide is a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 agonist, this class-level concern applies given the lack of human lactation data for this novel medication.

There are no published studies evaluating tirzepatide excretion into breast milk or its effects on nursing infants 2, 3, 4. Given that tirzepatide was only recently approved and represents a first-in-class dual incretin agonist, the absence of lactation safety data makes it inappropriate for use in breastfeeding women when safer alternatives exist.

Recommended Safe Alternatives for Diabetes Management During Breastfeeding

First-Line Option: Insulin

  • Insulin remains the gold standard for diabetes management during breastfeeding and is completely safe 1, 5.
  • Lactating women typically require approximately 34% less insulin than prepregnancy requirements initially due to calories expended with nursing 6.
  • Insulin sensitivity increases dramatically with placental delivery and returns to prepregnancy levels over 1-2 weeks 6.
  • Critical caveat: Lactation increases the risk of overnight hypoglycemia, requiring careful insulin dose adjustments and potentially a carbohydrate-containing snack before or during nursing 6, 1.

Second-Line Options: Oral Agents

  • Metformin: Excreted into breast milk but does not appear to have harmful neonatal effects in limited studies, though larger studies are needed 1.
  • Glyburide or glipizide: Can be safely used by breastfeeding women 1, 5.
  • Glipizide is preferred over glyburide among sulfonylureas due to its shorter duration of action, reducing maternal hypoglycemia risk 5.
  • Glipizide is not detectable in breast milk and does not cause hypoglycemia in nursing infants 5.

Critical Management Considerations for Breastfeeding Women with Diabetes

Nutritional Requirements

  • Energy requirements during the first 6 months of lactation require an additional 200 calories above the pregnancy meal plan 1.
  • An energy intake of 1,800 kcal/day usually meets nutritional requirements for lactation and may allow slow weight loss of 1-2 lb/month 1.
  • Adequate energy intake is critical to prevent ketosis during lactation 1.
  • Evening or late-night snacks may be necessary to prevent accelerated ketosis overnight 1.

Hypoglycemia Prevention

  • Breastfeeding lowers blood glucose, often requiring a carbohydrate-containing snack before or during nursing 1.
  • Particular attention should be directed to hypoglycemia prevention in the setting of breastfeeding and erratic sleep and eating schedules 6.

Benefits of Breastfeeding for Women with Diabetes

  • Breastfeeding should be strongly encouraged as it reduces the risk of developing type 2 diabetes in mothers with previous gestational diabetes (OR 0.68 [95% CI 0.57-0.82]) 6, 1.
  • For infants, breastfeeding reduces infant mortality from infectious diseases (OR 0.22-0.59), respiratory infections, and asthma risk (OR 0.91 [0.85-0.98]) 6, 1.
  • Breastfeeding is associated with reduced risks of breast cancer (OR 0.81 [95% CI 0.77-0.86]) and ovarian cancer (OR 0.70 [95% CI 0.64-0.75]) in mothers 6.

Common Pitfalls to Avoid

  • Do not continue tirzepatide from pregnancy into the postpartum period without considering lactation safety 1.
  • Do not assume that newer diabetes medications are automatically safe during breastfeeding simply because they are effective for glycemic control 1.
  • Do not forget to adjust insulin doses immediately postpartum, as insulin sensitivity increases dramatically with placental delivery 1.
  • Do not discontinue breastfeeding due to diabetes concerns—the metabolic benefits far outweigh the management challenges 1.

References

Guideline

Breastfeeding and Diabetes Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist.

Journal of diabetes and its complications, 2022

Guideline

Glipizide Use During Breastfeeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.